3DPrint.com | The Voice of 3D Printing / Additive Manufacturing

Q1 2016 Financial Results Just Released for Materialise

Overall, when it comes to discussing projections for the 3D printing industry, we hear that the dollar signs should be plentiful indeed as we ring in many more new years, new products, and new materials. The subject can become confusing though when we see large companies though like 3D Systems and Stratasys showing numbers that range from terrible to less than stellar.

Questions abound as to why the larger companies aren’t holding it together more lucratively, but such is the way of big business and an ever changing and extremely competitive marketplace, with shakeups internally always causing upheaval, even if temporarily. Materialise, with Q1 2016 results just released, now demonstrates revenues in line with the Street estimate, although with a greater net loss than expected.

Materialise Magics Software

The Belgium-headquartered company shows that for the first quarter ending March 31, 2016, there were indeed numerous increases, to include the following:

Peter Leys, Materialise Executive Chairman

“In the first quarter, we continued to execute on our strategy of strengthening Materialise’s position as a leading enabler of 3D printing applications and performed in line with our expectations. Revenue rose 14.2% and Adjusted EBITDA increased from (288) kEUR to 1,135 kEUR,” states Executive Chairman Peter Leys.

 

“In Materialise Software, we have been taking the final steps to launch our Magics 3D Print Suite, supporting our positioning as the backbone of industrial 3D Printing. In Materialise Medical, we launched our Mimics Care Suite, designed to accelerate the integration of certified medical 3D printing within hospitals. In Materialise Manufacturing, we have been making progress in establishing partnerships with market leaders to further our goal of participating in meaningful end part manufacturing projects.”

Gross profit was 15,962 kEUR, or 59.9% of revenue, for the first quarter of 2016 compared to 13,467 kEUR, or 57.7% of revenue, for the first quarter of 2015, resulting from a continued shift of a revenue mix towards both industrial and medical software licenses as well as an improvement of the gross margin of the Materialise Manufacturing segment.

According to Materialise, research and development, sales and marketing, and general and administrative expenses increased, in the aggregate, by 5.4% to 18,237 kEUR from 17,297 kEUR for the first quarter of 2015. While R&D expenses remained relatively stable, moving from 4,507 kEUR to 4,372 kEUR, S&M expenses decreased modestly from 9,215 kEUR to 8,815 kEUR, and G&A expenses increased from 3,575 kEUR to 5,050 kEUR. Materialise sees these changes as a result of new managerial ‘structure and support’ that’s been implemented over the past 18 months in both R&D and S&M—and indeed, these have been put in place due to significant growth requiring greater resources.

“A number of employees with mixed roles within these groups have evolved into more managerial/administrative roles, and their cost as well as certain other expenses are now categorized into G&A,” states the company.

In terms of decreases and losses, Materialise reported the following:

As of March 31, 2016, the company had cash and equivalents of 49,435 kEUR compared to 50,726 kEUR at December 31, 2015. Cash flow from operating activities in the first quarter of 2016 was 1,376 kEUR. Net shareholders’ equity at March 31, 2016 was 79,028 kEUR, a decrease of 3,927 kEUR since December 31, 2015.

The stock increased 1.85% or $0.12 on May 10, hitting $6.87.

2016 Guidance from Materialise is as follows:

“As detailed in the company’s year-end fiscal 2015 earnings announcement, in fiscal 2016 management expects to report consolidated revenue between 115,000 – 120,000 kEUR and Adjusted EBITDA between 7,000 – 9,000 kEUR. Management also expects the amount of deferred revenue the company generates from annual licenses and maintenance to increase by an amount between 3,000 – 4,000 kEUR from 13,136 kEUR as of December 31, 2015.”

A conference call regarding financial results for Q1 was held this morning at 8:30 a.m., with the following participating: Wilfried Vancraen, Founder and Chief Executive Officer; Peter Leys, Executive Chairman; and Johan Albrecht, Chief Financial Officer. If you are interested in hearing a replay of this, you may gain access by dialing 855-859-2056 (international participants should dial 404-537-3406). The access code for the replay is #88439870. Materialise states that a webcast of the conference call and slide presentation will be archived on the company’s website for one year.

Materialise, although headquartered in Belgium, is a company that has been in business for over 25 years, and is respected worldwide. Known for their software development, as well as one of the largest printing facilities, we follow their activities continually, with an emphasis on their contributions to the medical sector, from helping to create the world’s first 3D printed wheelchair to their ongoing work in offering superior software, which has been responsible for assisting in cases such as that of an innovative and successful jaw replacement surgery.

Unless otherwise noted, all translations from euros to US dollars were made at a rate of EUR 1.00 to USD 1.1385, the 12:00 noon ET buying rate of the Federal Reserve Bank of New York for the euro on March 31, 2016. Did you see any surprises here? Discuss in the Materialise Q1 2016 Financial Report forum over at 3DPB.com.

[Sources: Business Wire; Sonoran Weekly Review ]

Consolidated income statements (Unaudited)

For the three months ended March 31

2016

2016

2015

(In thousands, except EPS)

U.S. $

Revenue 30,360 26,667 23,348
Cost of Sales (12,188) (10,705) (9,881)
Gross Profit 18,172 15,962 13,467
Research and development expenses (4,978) (4,372) (4,507)
Sales and marketing expenses (10,036) (8,815) (9,215)
General and administrative expenses (5,749) (5,050) (3,575)
Net other operating income (expenses) 1,464 1,286 1,780
Operating (Loss) Profit (1,127) (989) (2,050)
Financial expenses (1,021) (897) (449)
Financial income 186 163 1,921
Share in loss of a joint venture (191) (168) (60)
Profit before taxes (2,153) (1,891) (638)
Income Taxes (benefit) (1,435) (1,260) (250)
Net profit (loss) (3,588) (3,151) (888)
Net profit (loss) attributable to:
The owners of the parent (3,588) (3,151) (835)
Non-controlling interest (53)
EPS attributable to the owners of the parent
Basic (0.08) (0.07) (0.02)
Diluted (0.08) (0.07) (0.02)
Weighted average basic shares outstanding

47,325

47,325

47,170

Weighted average fully diluted shares outstanding

47,325

47,325

47,170

Consolidated statements of comprehensive income (Unaudited)

For the three months ended March 31

(In thousands)

2016

2016

2015

U.S. $

Net profit (loss) for the year (3,588) (3,151) (888)
Other comprehensive income
Exchange differences on translation of foreign operations (1,098) (964) 1,313
Other comprehensive income (loss), net of taxes (1,098) (964) 1,313
Total comprehensive income (loss) for the year, net of taxes (4,686) (4,115) 425
Total comprehensive income (loss) attributable to:

The owners of the parent

(4,686)

(4,115) 478

Non-controlling interest

(53)

Consolidated statements of financial position (Unaudited)

(in thousands of euros)

As of

March 31,

As of
December 31,

2016 2015
Assets
Current assets
Inventory 5,172 5,387
Trade receivables 23,152 22,843
Other current assets 4,981 4,993
Held to maturity investments
Cash and cash equivalent 49,435 50,726
Total current assets 82,740 83,949
Non-current assets
Goodwill 9,269 9,664
Intangible assets 9,059 9,657
Property, plant & equipment 38,102 38,400
Investments in joint ventures 850 1,018
Deferred tax assets 109 1,092
Other financial assets 323 356
Total non-current assets 57,712 60,187
Total assets 140,452 144,136
Equity and liabilities
Current liabilities
Loans & borrowings 4,137 4,482
Trade Payables 8,470 9,712
Tax Payables 495 255
Deferred income 18,116 16,509
Other current liabilities 9,252 9,212
Total current liabilities 40,470 40,170
Non-current liabilities
Loans & borrowings 16,605 16,607
Deferred tax liabilities 1,953 2,068
Deferred income 65 92
Other non-current liabilities 2,331 2,244
Total non-current liabilities 20,954 21,011
Net equity
Share capital 2,729 2,729
Share premium 78,284 78,098
Consolidated reserves (1,742 ) 1,407
Other comprehensive income (loss) (243 ) 721
Equity attributable to the owners of the parent 79,028 82,955
Non-controlling interest
Total equity 79,028 82,955
Total equity and liabilities 140,452 144,136

Consolidated cash flow statements (Unaudited)

(in thousands of euros) For the three months ended

March 31,
2016

March 31,
2015

Operating activities
Net profit (loss) for the period (3,151) (888)
Non-cash and operating adjustments
Depreciation of property, plant & equipment 1,448 1,219
Amortization of intangible assets 462 323
Share-based payment expense 214 220
Loss (gain) on disposal of property, plant & equipment (111)
Fair value adjustment contingent liabilities
Movement in provisions and allowance for bad debt 42 (2)
Financial income (48) (137)
Financial expense 254 240
Impact of foreign currencies 528 (2,024)
Share of loss in a joint venture 168 60
Deferred tax expense (income) 868 171
Income taxes 358 79
Other (5)
Working capital adjustments
Increase in trade receivables and other receivables (285) (1,364)
Decrease (increase) in inventories 215 (775)
Increase in trade payables and other payables 421 3,988
Income taxes paid (118) (176)
Net cash flow from operating activities 1,376 818
Investing activities
Purchase of property, plant & equipment (1,325) (2,809)
Purchase of intangible assets (265) (234)
Proceeds from the sale of property, plant & equipment, net 85 2,535
Acquisition of subsidiaries (1,797)
Investments in joint-ventures (500)
Investments in held to maturity investments 3,000
Interest received 3 49
Net cash flow used in investing activities (1,502) 244
Financing activities
Proceeds from loans & borrowings and convertible debt 604 269
Repayment of loans & borrowings (656) (2,320)
Repayment of finance leases (419) (342)
Purchase of non-controlling interest (1,377)
Capital increase in parent company 580
Interest paid (141) (137)
Other financial income (expense) (33) (32)
Net cash flow from financing activities (645) (3,359)
Net increase of cash and cash equivalents (771) (2,297)
Cash and cash equivalents at beginning of period 50,726 51,019
Exchange rate differences on cash & cash equivalents (520) 1,849
Cash & cash equivalents at end of period 49,435 50,571

Segment P&L (Unaudited)

(In thousands of euros, except percentages)

Materialise
Software

Materialise
Medical

Materialise
Manufacturing

Total
Segments

Adjustments &
Eliminations

Consolidated

For the three month period ended March 31, 2016

Revenues 7,431 8,606 10,606 26,643 24 26,667
Segment EBITDA 2,765 (530 ) 257 2,492 (1,571 ) 921
Segment EBITDA % 37.2 % (6.2 )% 2.4 % 9.4 % 3.5 %

For the three month period ended March 31, 2015

Revenues 6,116 7,848 9,384 23,348 23,348
Segment EBITDA 2,215 (746 ) (40 ) 1,429 (1,937 ) (508 )
Segment EBITDA % 36.2 % (9.5 )% (0.4 )% 6.1 % (2.2 )%

Reconciliation of Net Profit/(Loss) to EBITDA and Adjusted EBITDA (Unaudited)

For the three months
ended March 31

(in thousands of euros) 2016 2015
Net profit/(loss) (3,151) (888)
Income taxes 1,260 250
Financial expenses 897 449
Financial income (163) (1,921)
Share in loss of a joint venture 168 60
Depreciation & amortization 1,910 1,542
EBITDA 921 (508)
Non-recurring IPO expenses(1) 0 0

Non-cash stock-based compensation
expenses(2)

214 220
Adjusted EBITDA 1,135 (288)

(1) Non-recurring IPO expenses represent fees and costs incurred in connection with the company’s initial public offering.

(2) Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees.

Exit mobile version